Pain Therapeutics公 PTIE 深 沪
等待开盘 09-19 09:30:00 美东时间
1.24
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 1.24
- 总市值 2066.00万
- 52周最高 2.99
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.76
- 委 比 0.00%
- 总股本 1666.13万
- 历史最高 43.54
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.76
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory
CNSide Diagnostics, a subsidiary of Plus Therapeutics, Inc., has received a CLIA certification from the Centers for Medicare & Medicaid Services (CMS) for its Houston-based lab. This certification is a crucial step toward broad U.S. market release of the CNSide CSF Assay Platform, meeting federal and state regulatory requirements. It enables the company to pursue state licensure, secure insurance coverage, and expand payment coding, supporting th...
09-18 11:30
Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases
Plus Therapeutics, Inc. announced positive results from the ReSPECT-LM Phase 1 trial of REYOBIQ for treating leptomeningeal metastases (LM). The study showed a clinical benefit rate over 75%, significant tumor cell reduction, and a favorable safety profile with no dose-limiting toxicities observed. Median overall survival was 9 months, compared to the typical 2-6 months for LM patients. Results support the recommended phase 2 dose of 44.1 mCi and...
08-18 11:30
PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System
PainReform Ltd. has acquired a majority stake in LayerBio Inc., a biotech company developing "dropless" solutions for ophthalmic surgery. The investment focuses on advancing LayerBio’s OcuRing™-K, a sustained-release intraocular ring designed to deliver anti-inflammatory and analgesic medication during cataract surgery, addressing patient compliance issues and reducing reliance on multiple medications. This transaction positions PainReform to add...
08-13 12:30
Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic
Houston-based Plus Therapeutics subsidiary CNSide Diagnostics will launch its CSF assay platform for detecting cancer metastases in the central nervous system in Texas in August 2025. The initial commercial focus will be on NCI-Designated Cancer Centers and large healthcare systems. The CNSide assay offers high sensitivity (92%) and specificity (95%), surpassing traditional CSF cytology methods. It has been used in over 11,000 tests since 2020 an...
07-31 11:30
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference
HOUSTON, July 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. announced that its subsidiary, CNSide Diagnostics, will present two studies at the upcoming SNO/ASCO CNS Metastases Conference on August 14-16, 2025, in Baltimore, MD. The studies focus on the clinical utility of the CNSide CSF Assay Platform for detecting and quantifying tumor cells in cerebrospinal fluid (CSF) in patients with leptomeningeal disease. Priya Kumthekar, M.D., will ...
07-10 11:30
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary
Plus Therapeutics, Inc. will commercially launch its CNSide CSF Assay Platform for diagnosing CNS metastases in the U.S. in late 2025, targeting a $6+ billion underserved market. The platform, which offers superior sensitivity (92%) and specificity (95%) compared to traditional methods, has been used in over 11,000 tests since 2020. The company plans rapid expansion across the U.S. and has secured payor agreements. Management will host a conferen...
06-26 11:30
Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer
Plus Therapeutics announced FDA clearance for its IND application for REYOBIQ™, a targeted radiotherapeutic, in a Phase 1/2a clinical trial for pediatric patients with recurrent, refractory, or progressive high-grade glioma and ependymoma. The trial, named ReSPECT-PBC, is funded by a $3.0M grant from the U.S. Department of Defense. The study aims to determine the maximum tolerated dose and assess safety, tolerability, and efficacy. REYOBIQ™ lever...
06-25 11:30
Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing
Plus Therapeutics announced a restructuring of its March 2025 $15 million equity financing to eliminate potential dilution of up to 1.5 billion shares, enhancing shareholder value and simplifying its capital structure. Key changes include canceling dilutive warrants, removing 25 million shares of common stock, and using 90% of future proceeds to repay March 2025 financing holders at 115% of their original investment. The company also withdrew the...
06-24 11:30
疼死了有多疼？疼痛指数如何推动了癌症治疗？
本文来自微信公众号：CC情报局 （ID：cancer-weekly），作者：陈颀（德克萨斯大学奥斯汀分校社会工作博士生），原文标题：《疼死了有多疼？发明疼痛指数...
2022-07-07 16:18
在中国麻醉周 认识这群“生命的守护神”
■文/廖宏龙 通讯员：诸胜涛 指导医生：嘉兴市第一医院麻醉手术部副主任、主任医师 陆雅萍 特别采访：嘉兴市第一医院院长、浙北麻醉学区域专病中心主任...
2022-03-30 06:36
